Related references
Note: Only part of the references are listed.Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer
Giampaolo Perri et al.
ANNALS OF SURGERY (2021)
Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence
Philip C. Mueller et al.
PHARMACOLOGY (2021)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Jia-qiao Fan et al.
MOLECULAR CANCER (2020)
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Paula Ghaneh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines
Francesco Cellini et al.
CANCERS (2020)
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
Yuji Eso et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Erik Henke et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Antonio B. Ward et al.
MEDCOMM (2020)
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
Yang Wang et al.
SCIENTIFIC REPORTS (2019)
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
Theodoros Michelakos et al.
ANNALS OF SURGERY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
V Kunzmann et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Fuyuhiko Motoi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
Jin-Young Jang et al.
ANNALS OF SURGERY (2018)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Abul Azad et al.
EMBO MOLECULAR MEDICINE (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.
Austin G. Duffy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Share Paper
